Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAK 683

Next Previous
Drug Profile

MAK 683

Alternative Names: MAK-683

Latest Information Update: 14 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antineoplastics
  • Mechanism of Action Polycomb repressive complex 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours

Most Recent Events

  • 31 Oct 2024 Novartis Pharmaceuticals terminates phase-I/II development in Solid tumours (Late-stage disease, Metastatic disease, Recurrent) is ongoing in Canada, China, France, Germany, Hong Kong, Italy, Japan, Singapore, Spain, USA due to business reasons (NCT02900651)
  • 03 Jun 2022 Pharmacodynamics and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 18 Feb 2022 Phase-I/II development in Lymphoma (Late-stage disease, Metastatic disease, Recurrent) is ongoing in Canada, China, France, Germany, Hong Kong, Italy, Japan, Singapore, Spain, USA (PO) (NCT02900651) (EudraCT2016-001860-12)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top